Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

GC Biopharma Corp (006280)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
111,500 -500    -0.45%
02:40:00 - Closed. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7006280002 
  • Volume: 12,174
  • Bid/Ask: 111,400 / 111,500
  • Day's Range: 110,800 - 113,300
GC Biopharma 111,500 -500 -0.45%

006280 Balance Sheet

 
Featured here, the Balance Sheet for GC Biopharma Corp, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 1039147.71 1125593.11 1028807.06 1003922.21
Cash and Short Term Investments 55506.13 70301.02 80679.77 95453.33
Cash - - - -
Cash & Equivalents 49706.13 64501.02 76879.77 82653.33
Short Term Investments -0 - - -0
Total Receivables, Net 450932.74 522502.71 421035.89 409558.93
Accounts Receivables - Trade, Net 436956.74 508868.71 407976.89 393840.93
Total Inventory 516245.34 515450.61 508335.67 482090.48
Prepaid Expenses 4147 4039 4899 5304
Other Current Assets, Total 12316.5 13299.76 13856.73 11515.47
Total Assets 2643313.92 2677751.94 2577540.54 2555302.31
Property/Plant/Equipment, Total - Net 952702.74 926555.85 925326.89 929021.53
Property/Plant/Equipment, Total - Gross 1357503.74 926555.85 925326.89 1300729.53
Accumulated Depreciation, Total -404801 - - -371708
Goodwill, Net 142475 - - 142475
Intangibles, Net 86166.07 332329.43 331114.08 81399
Long Term Investments 206646.14 211998.55 208391.31 213847.01
Note Receivable - Long Term 11976 10134 9559 14218
Other Long Term Assets, Total 68972.02 49557.36 49492.11 57559.03
Other Assets, Total 232633.34 47265.31 142865.61 225425.54
Total Current Liabilities 868916.64 877662.27 808748.06 613582.81
Accounts Payable 143815.7 146918.05 148970.11 144976.63
Payable/Accrued - - - -
Accrued Expenses 34000 29824 28517 67408
Notes Payable/Short Term Debt 315447 384561.12 314207.47 243000.34
Current Port. of LT Debt/Capital Leases 217148.83 193190.58 192505.18 30953.51
Other Current liabilities, Total 158505.11 123168.52 124548.31 127244.33
Total Liabilities 1103450.61 1125709.08 1047898.55 1029444.82
Total Long Term Debt 191426.33 187815.8 183521.19 364163.6
Long Term Debt 84890.7 91241.46 86041.82 266278.43
Capital Lease Obligations 106535.63 96574.34 97479.37 97885.17
Deferred Income Tax 2213.06 1475.7 1331.12 934.67
Minority Interest 239627.02 241330.94 236268.27 235094.03
Other Liabilities, Total -514179.43 -766136.75 -496177.55 -532746.63
Total Equity 1539863.31 1552042.86 1529641.99 1525857.49
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 58432.69 58432.69 58432.69 58432.69
Additional Paid-In Capital 393604.69 393604.69 393604.69 393604.69
Retained Earnings (Accumulated Deficit) 872988.97 876712.73 862790.97 861022.79
Treasury Stock - Common -35701.77 -35701.77 -35701.77 -35701.77
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 250538.73 258994.51 250515.41 248499.09
Total Liabilities & Shareholders' Equity 2643313.92 2677751.94 2577540.54 2555302.31
Total Common Shares Outstanding 11.41 11.41 11.41 11.41
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

006280 Comments

Write your thoughts about GC Biopharma Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email